Wpd Pharmaceuticals Inc · CSE:WBIO
Wpd Pharmaceuticals — Investor Presentation (April 2021)
21 slides from Wpd Pharmaceuticals's investor presentation, April 2021
Slide 1: WPD Pharmaceuticals Investor Presentation April 2021
WPD Pharmaceuticals APRIL 2021 | INVESTOR PRESENTATION CSE:WBIO Investor Presentation April 2020 | CSE:WBIO |
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words "believe",
Slide 3: Company Overview
Company Overview WPD Pharmaceuticals is a diverse biotech company with 10 novel drug candidates, including 4 in clinical development stage. Licensed drug candidates were discovered and studied at premier USA research institutions, such as: MD Anderson Cancer Center, Mayo Clinic, Emory University, Wa
Slide 4: Investment Highlights
Investment Highlights Experienced Management & Advisors Robust Drug Portfolio Strategic Partnerships Team of scientists with extensive 10 novel drug candidates across 5 pharmaceutical experience indications Wake Forest University Health Sciences, Moleculin Biotech Inc. and CNS Pharmaceuticals, Inc.
Slide 5: World-Class Pharmaceutical Team
Word-Class Pharmaceutical Team Investor Presentation | CSE:WBIO | 5
Slide 6: Team
TEA M | W P D P H A R M A C E U T I C A L S . C O M | 6 CEO & CO-FOUNDER COO Experienced professional in Biologist experienced in clinical development - from medical biology, immunology, planning and scientific advice and cardiovascular medicine. through supervision to the Investigator in several re
Slide 7: Board of Directors
B O A R D OF D I R E C T O R S | W P D P H A R M A C E U T I C A L S . C O M | 7 BOARD MEMBER 15 years of experience working with junior resources com- BOARD MEMBER, CANADIAN panies, with particular focus BOARD MEMBER VICE PRESIDENT OF LEGAL, on accounting and fi- nance. Mr. Klemp has 29 years of CO
Slide 8: Scientific Advisory Board
Scientific Advisory Board Dr. Sigmund Hsu Dr. Waldemar Priebe SCIENTIFIC ADVISORY BOARD MEMBER FOUNDER CHAIRMAN OF SCIENTIFIC ADVISORY BOARD Dr. Waldemar Priebe, Ph.D., is a world renowned medicinal chemist and entrepreneur. Dr. Priebe is a Professor of Medicinal Chemistry in the Department of Exper
Slide 9: 10 Drugs 5 Indications
10 Drugs 5 Indications Investor Presentation | CSE:WBIO | 9
Slide 10: Drug Pipeline by Indication and Stage
Discovery Pre-Clinical Regulatory Clinical I / II Brain Cancers WPD101 Berubicin WP1066 Pancreatic Cancers WPD1122 WP1066 WPD1234 WP1732 Other Cancers WPD103 Annamycin WPD1220 Melanoma WPD102 Investor Presentation April 2020 | CSE:WBIO | 10
Slide 11: Berubicin - Indications to Treat Glioblastoma
Berubicin - Indications to Treat Glioblastoma OVERVIEW A new anthracycline proven to be able to reach brain tumors by crossing the blood brain barrier (BBB) and developed in the treatment of glioma. STRATEGY Phase I clinical studies showed promising therapeutic effects in the GBM patients with one c
Slide 12: WPD101 - Indications to Treat Brain Cancers, including Glioblastoma
WPD101 - Indications to Treat Brain Cancers, including Glioblastoma OVERVIEW Interluekin-13 receptor alpha 2 (IL13RA2) is a glioblastoma receptor overexpressed in >75% of GBMs and reported in >50% of GBM cases. EphA2 is cancer- specific receptor recognized by ephrin A1 cytokine. Its overexpression i
Slide 13: WP1122 - Indications to Treat SARS-CoV-2 Infection
WP1122 - Indications to Treat SARS-CoV-2 Infection OVERVIEW SARS-CoV-2 upregulates glycolysis process in infected cells to generate ATP necessary for fast virus replication, therefore inhibition of glycolysis could be an effective antiviral strategy. 2-deoxy-D-glucose (2-DG) is a synthetic analogue
Slide 14: Annamycin - Indications to treat AML, metastasis to lungs
Annamycin - Indications to treat AML, metastasis to lungs OVERVIEW A derivative of doxorubicin, which facilitates the rapid penetration of the drug and the effective delivery of Annamycin to cancer cells, effectively limiting adverse effects on myocardial cells. STRATEGY In vitro and in vivo preclin
Slide 15: Other drug candidates – current status
Other drug candidates – current status WPD1066 In the Phase I trial at MD Anderson Cancer Center for GBM and melanoma metastasized to the brain, in the third cohort of dose escalation evaluating safety and activity. WPD plans surgical expansion to assess tumor tissue directly after administration of
Slide 16: Corporate Overview: Capital Structure
Corporate Overview WPD Pharmaceuticals Inc. Capital Structure Issued and Outstanding 111,520,388 CSE: WBIO Warrants Fully Diluted 3,949,997 115,470,385 Management and Insider holdings 36% Investor Presentation April 2020 | CSE:WBIO | 16
Slide 17: Contact us for more details
Contact us for more details Vancouver Office Warsaw Office Suite 1080 Żwirki i Wigury 101 789 West Pender St 02-089 Warszawa Vancouver, BC V6C 1H2 Poland wpdpharmaceuticals.com CSE:WBIO Investor Presentation April 2020 | CSE:WBIO |
Slide 18: Appendix / References
Appendix / References: 1. Bojkova D., Klann K., Koch B., Widera M., Krause D., Ciesek S., Cinatl J., Munch C. Proteomics of SARS-CoV-2-infected host cells reveals therapy genes. Nature 2020, 583:469-472. 2. Brooks TA, O’Loughlin KL., Minderman H., Bundy BN., Ford LA., Vredenburg MR., Bernacki RJ., P
Slide 19: References
References: 15. Inge TH., Harris NL., Wu J., Azizkhan RG., Priebe W. WP744 is a novel anthracycline with enhanced activity against neuroblastoma. J Surg Res 2004, 121:187-96. 16. Kawakami K., Kawakami M., Joshi B., Puri RK. Interleuki-13-receptor-targeted cancer therapy in an immunodeficient animal
Slide 20: References
References: 28. Sattiraju A., Solingapuram Sai KK., Xuan A., Pandya DN., Almageul FG., Wadas TJ., Herpal DM., Debisnki W., Mintz A. IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget 2017, 27:42997-43007. 29. Sau S., Mondal SK., Kashaw SK., Iyer AK., Banerjee R. Combination of
Slide 21: References
References: 41. Wykosky J., Gibo DM., Stanton C., Debinski W. Interleukin -13-receptor alpha 2, EphA2 and Fos- related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 2008; 14:199-208. 42. Yu J., Yan X., Liu Y., Zhang K.,
WPD Pharmaceuticals — Investor Presentation (April 2021) on 6ix